CD44 and breast carcinoma: Diehn et al. observed that ROS levels in CD44+/CD24− breast cancer CSCs were lower than in non-CSCs, and the expression levels of the modulatory subunit of glutamate cysteine ligase (GCLM, the rate-limiting enzyme of GSH synthesis) and FoxO1 were high.